Decision to list medical devices supplied by Bunzl Outsourcing Services NZ Limited, B. Braun New Zealand Pty Limited and Smith & Nephew Limited

Hospital devices

Decision

We are pleased to announce the approval of non-exclusive listing agreements with Bunzl Outsourcing Services NZ Limited, B. Braun New Zealand Pty Limited and Smith & Nephew Limited for the supply of continence and urology products to DHBs.

What we’re doing

We are pleased to announce the approval of non-exclusive listing agreements with Bunzl Outsourcing Services NZ Limited (“Bunzl”), B. Braun New Zealand Pty Limited (“B. Braun”) and Smith & Nephew Limited (“Smith & Nephew”) for the supply of continence and urology products to DHBs.

In summary, this will result in the following ranges being listed in Part III of Section H of the Pharmaceutical Schedule from 1 July 2019:

  • Bunzl’s range of continence products
  • B. Braun’s range of urology products
  • Smith & Nephew’s range of continence products

DHBs will be able to continue to purchase other suppliers’ brands of continence and urology products as the agreement are not for sole supply.

Any changes to the original proposals?

This decision was subject to the following consultations:

No changes were made to the original proposals as a result of consultation feedback.

Who we think will be most interested

  • Suppliers and Wholesalers
  • DHB Staff
    • clinical staff in a range of inpatient, outpatient and community settings where continence products are used
    • procurement and supply chain personnel

Detail about this decision

In May 2018, PHARMAC issued a request for proposals (“RFP”) for the supply of urology, ostomy and continence products to DHBs.

The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

After evaluating Bunzl’s, B. Braun’s and Smith & Nephew’s proposals, and consulting on the provisional agreements reached with them, PHARMAC has decided to list Bunzl’s and Smith & Nephew’s continence products, and B. Braun’s urology products, in Part III of Section H of the Pharmaceutical Schedule from 1 July 2019.

The brands included in the Bunzl agreement are:

Continence

  • ABRI-FIX
  • ABRI-FLEX BARIATRIC
  • ABRI-FLEX PREMIUM
  • ABRI-FORM COMFORT
  • ABRI-FORM PREMIUM
  • ABRI-SAN PREMIUM
  • ABRI-SOFT
  • BAMBO

The brands included in the B. Braun agreement are:

Urology

  • Medicare
  • Ureofix
  • Urimed

The brand included in the Smith & Nephew agreement is:

Continence

  • Secura

Our response to what you told us

We appreciate the time people took to consider this consultation.

All consultation responses received by 29 May 2019 for the Bunzl and B. Braun proposals, and by 31 May 2019 for the Smith & Nephew proposal, were considered in their entirety in making the decision to approve each agreement.

A summary of the main themes raised in feedback and our responses to the feedback are set out below:

Theme

Comment

Bunzl, B. Braun and Smith & Nephew agreements

 

No technical or resource impacts are expected as a result of the proposals

Noted.

Smith & Nephew agreement

 

Query about the data provided to DHBs during consultation

Corrected data provided to all DHBs.

If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.